Compass Therapeutics Stock Overlap Studies Simple Moving Average
| CMPX Stock | USD 5.19 -0.40 -7.16% |
| Symbol |
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Compass Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Compass Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
Compass Therapeutics Technical Analysis Modules
Most technical analysis of Compass Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Compass from various momentum indicators to cycle indicators. When you analyze Compass charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. A high-level view of Compass Therapeutics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 4.73. Compass Therapeutics has a market cap of 994.25 M, ROE of -41.29%.
Methodology
Unless otherwise specified, financial data for Compass Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Compass (USA Stocks:CMPX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Compass Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Compass Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardBecome your own money manager
Tracking Compass Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested few shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Adviser Favorites Invested few shares | |
 | Blockchain Invested few shares | |
 | Artificial Intelligence Invested few shares | |
 | Corona Opportunity Invested few shares | |
 | SRI Sustainable Growth Invested few shares | |
 | Hedge Favorites Invested over 200 shares | |
 | ESG Investing Invested few shares | |
 | Driverless Cars Invested few shares | |
More Resources for Compass Stock Analysis
Reviewing Compass Therapeutics commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Compass Therapeutics Stock. Below are reports that help frame Compass Therapeutics Stock in context:Compass Therapeutics has a market cap of 994.25 M, ROE of -41.29%. See Trending Equities for portfolio-level analysis. This suggests a position in Compass Therapeutics across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Learn how to buy and trade Compass Stock using our step-by-step How to Buy Compass Therapeutics guide.Analysis related to Compass Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Investors evaluate Compass Therapeutics using market value and book value, each describing different facets of the business. Compass Therapeutics' market capitalization is 994.25 M. With a P/B ratio of 4.73, the market values Compass Therapeutics well above its book equity. Enterprise value stands at 784.22 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
The concept of value for Compass Therapeutics differs from its quoted price, since each reflects a different lens. For Compass Therapeutics, key inputs include a P/B ratio of 4.73, and ROE of -41.29%. By contrast, market price reflects the level where buyers and sellers transact.